Corcept Therapeutics Inc (CORT)
22.21
-0.27
(-1.20%)
USD |
NASDAQ |
Apr 25, 16:00
22.50
+0.29
(+1.31%)
Pre-Market: 20:00
Corcept Therapeutics Revenue (TTM): 482.38M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 482.38M |
| September 30, 2023 | 450.03M |
| June 30, 2023 | 428.15M |
| March 31, 2023 | 413.82M |
| December 31, 2022 | 401.86M |
| September 30, 2022 | 397.62M |
| June 30, 2022 | 392.03M |
| March 31, 2022 | 380.23M |
| December 31, 2021 | 365.98M |
| September 30, 2021 | 352.89M |
| June 30, 2021 | 343.09M |
| March 31, 2021 | 340.06M |
| December 31, 2020 | 353.87M |
| September 30, 2020 | 356.03M |
| June 30, 2020 | 351.21M |
| March 31, 2020 | 334.90M |
| December 31, 2019 | 306.49M |
| September 30, 2019 | 285.42M |
| June 30, 2019 | 268.36M |
| March 31, 2019 | 258.42M |
| December 31, 2018 | 251.25M |
| September 30, 2018 | 237.70M |
| June 30, 2018 | 216.01M |
| March 31, 2018 | 189.26M |
| December 31, 2017 | 159.20M |
| Date | Value |
|---|---|
| September 30, 2017 | 129.73M |
| June 30, 2017 | 108.70M |
| March 31, 2017 | 92.86M |
| December 31, 2016 | 81.32M |
| September 30, 2016 | 72.48M |
| June 30, 2016 | 64.01M |
| March 31, 2016 | 56.24M |
| December 31, 2015 | 50.29M |
| September 30, 2015 | 44.33M |
| June 30, 2015 | 38.35M |
| March 31, 2015 | 32.25M |
| December 31, 2014 | 26.55M |
| September 30, 2014 | 21.65M |
| June 30, 2014 | 17.00M |
| March 31, 2014 | 13.04M |
| December 31, 2013 | 10.36M |
| September 30, 2013 | 7.619M |
| June 30, 2013 | 6.04M |
| March 31, 2013 | 5.024M |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
268.36M
Minimum
Jun 2019
482.38M
Maximum
Dec 2023
368.65M
Average
356.03M
Median
Sep 2020
Revenue (TTM) Benchmarks
| Ultragenyx Pharmaceutical Inc | 434.25M |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Catalyst Pharmaceuticals Inc | 398.20M |
| United Therapeutics Corp | 2.328B |
| XOMA Corp | 4.758M |